For locally advanced prostate cancer, we are developing formulations of LHRH agonists with a very short half-life, encapsulated within species of capsules that have different dissolving times, so that LHRH is released in a cyclic manner every several days, so all or most of the radiation course could be delivered during sequential cycles of testosterone flare (Figure 6). This evidence concerns the gene GNRH1 and prostate cancer.